Top Page
Artrya Limited
(Sydney:AYA)
Artrya Limited (AYA) vs. iShares MSCI Australia ETF (EWA)
Artrya Limited Business Overview & Revenue Model
Artrya Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.00K | 28.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.60M | -15.99M | -13.25M | -552.00K | -202.00K | -38.51K |
| EBITDA | -21.92M | -16.21M | -13.96M | -10.51M | -16.40M | -4.01M |
| Net Income | -19.71M | -16.41M | -14.00M | -11.14M | -17.16M | -4.08M |
Balance Sheet | ||||||
| Total Assets | 92.19M | 23.68M | 19.01M | 33.09M | 43.87M | 52.22M |
| Cash, Cash Equivalents and Short-Term Investments | 76.67M | 11.33M | 7.28M | 20.41M | 35.56M | 50.13M |
| Total Debt | 546.00K | 624.00K | 949.00K | 1.21M | 1.37M | 84.42K |
| Total Liabilities | 2.84M | 2.39M | 2.21M | 2.53M | 3.23M | 1.17M |
| Stockholders Equity | 89.35M | 21.29M | 16.80M | 30.56M | 40.64M | 51.05M |
Cash Flow | ||||||
| Free Cash Flow | -21.38M | -14.53M | -15.41M | -16.69M | -15.99M | -3.55M |
| Operating Cash Flow | -21.08M | -14.27M | -15.41M | -10.74M | -9.61M | -1.49M |
| Investing Cash Flow | -30.30M | 7.00K | 2.71M | 16.27M | -26.59M | -1.86M |
| Financing Cash Flow | 90.07M | 18.46M | -299.00K | -245.00K | 38.53M | 14.10M |
Artrya Limited Technical Analysis
Artrya Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$18.13M | 3.95 | -17.05% | ― | 28.91% | -1050.00% | |
46 Neutral | AU$490.06M | -13.78 | -86.14% | ― | ― | 0.17% | |
44 Neutral | AU$45.05M | -5.70 | -13.83% | ― | 3.61% | -17.03% | |
43 Neutral | AU$80.50M | -6.64 | ― | ― | ― | ― | |
40 Underperform | AU$10.09M | -0.96 | ― | ― | -40.05% | -49.57% |
Artrya Limited Corporate Events
Artrya Limited reported a significant increase in its half-year loss for the six months to 31 December 2025, with the loss after tax attributable to owners widening 44.4% to $10.743 million from $7.441 million a year earlier. The company did not declare or pay any dividends for the period, but disclosed a sharp improvement in net tangible assets per share, which rose to 53.67 cents at 31 December 2025 from 14.61 cents at 30 June 2025, a move that may reflect capital restructuring or asset revaluation and is likely to draw close scrutiny from investors assessing the company’s financial trajectory.
The interim financial statements for the half-year were reviewed by the company’s auditors, with the review report included in the interim financial report. The absence of any noted audit dispute or qualification provides some reassurance on the reliability of the reported figures, even as the larger loss underscores the ongoing cost pressures and investment needs typical of growth-focused medtech businesses still working toward sustainable profitability.
The most recent analyst rating on (AU:AYA) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has notified the market of changes to its issued capital via an Appendix 3H filing, confirming the lapse of a tranche of performance rights. The update reflects routine capital management activity, with no additional context provided on operational performance or strategic direction.
The company reported that 613,334 performance rights, designated under the ASX code AYAAAF, have ceased due to the relevant conditions not being met or becoming incapable of satisfaction as of 20 February 2026. The cessation slightly reduces potential future dilution for existing shareholders but does not involve any cash movement or immediate impact on the company’s balance sheet.
The most recent analyst rating on (AU:AYA) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has secured in-principle participation from Dignity Health Arizona, part of CommonSpirit Health and one of the largest nonprofit healthcare systems in the United States, in its retrospective multi-centre SAPPHIRE Study, subject to final documentation and ethics approval. The study, set to launch in 2026, will evaluate the clinical and prognostic value of Artrya’s Salix AI-powered Plaque Analysis and proprietary Plaque Dispersion Score in identifying patients at elevated risk of cardiovascular events, with Dignity Health’s high-volume cardiovascular program expected to significantly enhance the scale and real-world relevance of the research. Artrya is also expanding the project to include SAPPHIRE-WIN, a women-only cohort focused on non-obstructive coronary artery disease, aiming to address longstanding diagnostic challenges and improve risk prediction and treatment outcomes for female patients, a group often underdiagnosed despite coronary artery disease being the leading cause of death among women globally.
The most recent analyst rating on (AU:AYA) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has secured in-principle participation from HCA Midwest Health in its upcoming retrospective, multi-centre SAPPHIRE Study in the United States, pending protocol and ethics approval. The inclusion of HCA Midwest Health, a high-volume cardiology provider in Kansas City led locally by advanced imaging specialist Dr Stephen Bloom, expands the geographic reach and clinical depth of the study, which is designed to evaluate the prognostic and clinical utility of Artrya’s Salix Plaque Analysis and Plaque Dispersion Score in identifying high-risk coronary artery disease patients more precisely than traditional risk models, potentially strengthening Artrya’s clinical evidence base and positioning in the U.S. cardiovascular imaging market ahead of the study’s planned 2026 launch.
The most recent analyst rating on (AU:AYA) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has appointed Richard Jarvis of The CFO Bridge as interim Chief Financial Officer, effective immediately, while it undertakes an executive search with Stanton Chase for a permanent CFO to lead the finance function through its next growth phase. The move is part of a broader effort to strengthen the leadership team as Artrya progresses the commercialisation of its Salix AI platform and expands its presence in the U.S. market, with management emphasising the need for seasoned executives who can support scaling the business, drive commercial outcomes and underpin the company’s growth strategy.
The most recent analyst rating on (AU:AYA) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has signed a five-year commercial software-as-a-service agreement with Cone Health, a major not-for-profit health system in North Carolina, marking the company’s third U.S. commercial customer for its Salix AI platform. Under the deal, Cone Health will deploy the Salix Coronary Anatomy module on a subscription basis across its network of hospitals and cardiology practices, with additional per-scan revenue for use of the Salix Coronary Plaque module, which is eligible for U.S. reimbursement, while onboarding and ongoing support will be handled by Artrya’s U.S.-based Customer Success team in Atlanta. The agreement, valued at a minimum of US$0.45 million over five years, completes the conversion of all three of Artrya’s U.S. foundation partners into paying customers in 2025, underscoring growing commercial momentum ahead of 2026 and strengthening the company’s foothold in the competitive U.S. cardiac imaging and diagnostics market.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has announced its first revenue generation from the Salix® Coronary Plaque module, following its integration into Tanner Health’s workflow in the U.S. This marks a significant milestone for Artrya as it expands its U.S. revenue opportunities through subscription and fee-per-scan models, supported by a U.S. Category 1 CPT reimbursement rate. The successful activation and integration of the module, facilitated by Artrya’s customer support team, is expected to enhance patient care and streamline operations at Tanner Health, potentially leading to broader adoption across their network.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
Artrya Limited has secured a three-year commercial agreement with Northeast Georgia Health System (NGHS), marking its second U.S. customer for the Salix® platform. The agreement, valued at a minimum of US$0.3 million, includes a SaaS license for the Salix® Coronary Anatomy platform and fee-per-scan revenue from the Salix® Coronary Plaque module, with potential expansion upon FDA clearance of the Salix® Coronary Flow module. This partnership is a significant step in Artrya’s U.S. expansion strategy, integrating its AI-powered platform into NGHS’s clinical workflow to enhance cardiovascular care and diagnostic precision. The rollout will be supported by Artrya’s Customer Success team in Atlanta, ensuring seamless integration and support for NGHS’s network of hospitals and the Georgia Heart Institute.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.